Steven Templeton, DO
Critical Care Medicine · Columbia, SCNPI 1831578822
Payments from drug & device makers
What this record shows
26 manufacturers reported payments, led by Medical Device Business Services, Inc. at 32.2% of the total.
Across 142 payments — averaging $43.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$2K
- Noah Medical Corporation$1K
- GSK$490
- Gilead$279
- Insmed, Inc.$193
- Baxter Healthcare$184
- plus $2K from 20 others
What the payments were for
- Travel & lodging$2,73544%
- Food & beverage$3,43156%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 7 | $1,983 |
| Noah Medical Corporation | 8 | $1,377 |
| GSK | 30 | $490 |
| Gilead | 11 | $279 |
| Insmed, Inc. | 10 | $193 |
| Baxter Healthcare | 8 | $184 |
| Galvanize Therapeutics, Inc | 2 | $180 |
| Regeneron Healthcare Solutions, Inc. | 7 | $178 |
| Inari Medical, Inc. | 4 | $156 |
| AstraZeneca | 8 | $155 |
| United Therapeutics Corporation | 5 | $145 |
| Boehringer Ingelheim | 6 | $112 |
| Sanofi | 4 | $101 |
| Actelion Pharmaceuticals US, Inc. | 4 | $88 |
| Verona Pharma, Inc. | 4 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $73 |
| Philips North America LLC | 4 | $72 |
| Amgen | 3 | $53 |
| Mylan Specialty L.p. | 3 | $52 |
| Merck | 2 | $45 |
| ANI Pharmaceuticals, Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $37 |
| La Jolla Pharmaceutical Company | 2 | $33 |
| Viatris Specialty LLC | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GALAXY$1,208
- ALIYA SYSTEM$148
How this compares
$6,166 in reported general payments places this provider in the 80th percentile of 93 critical care medicine providers in South Carolina.
See all critical care medicine providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 25 | $328,289 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 186 | $153,351 |
| Fasenra PenBenralizumab | 17 | $93,306 |
| TezspireTezepelumab-Ekko | 18 | $73,880 |
| Dupixent PenDupilumab | 17 | $63,221 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 80 | $38,090 |
| Spiriva RespimatTiotropium Bromide | 34 | $26,578 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $22,218 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $18,151 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $17,674 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $6,403 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 190 | $6,395 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $4,145 |
| Azelastine Hcl | 22 | $738 |
| Ventolin HfaAlbuterol Sulfate | 12 | $640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $112 | $354,86759 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $490 | $227,266348 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $155 | $96,09744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 93 critical care medicine providers in South Carolina.
Other critical care medicine in Columbia
- Jay KirkhamColumbia$2K
- Linda WilkersonColumbia$2K
- David SchriftColumbia$433
- William OwensColumbia$265
- Charlton StrangeCharleston$205K
- William AlleyneRock Hill$199K
- Rahul ArgulaCharleston$186K
- James CarswellCharleston$159K
- Daniel HerrHilton Head Island$151K
- Hafez HayekConway$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.